According to Tonghe Pharmaceutical's announcement, the company recently received a drug GMP compliance inspection notice from the Jiangxi Drug Administration. After on-site inspection and comprehensive assessment, the company's active ingredient edoxaban toluene sulfonate complies with the GMP requirements. The scope of inspection is an active ingredient. The inspection date is August 25, 2026 to August 29, 2026. Edoxaban toluene sulfonate is an oral anticoagulant drug mainly used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to treat or prevent deep vein thrombosis and pulmonary embolism. The inspection of this API will help the company expand sales in the domestic market, and there is some uncertainty about its specific sales situation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.